Onconova Therapeutics
ONTX
$0.72
Share price
-2.05%
Change (1 day)
-63.14%
Change (1 year)
Categories
P/S ratio for Onconova Therapeutics (ONTX)
P/S ratio as of March 2023 (TTM): 66.2
According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 66.2039. At the end of 2022 the company had a P/S ratio of 81.5.
P/S ratio history for Onconova Therapeutics from 2013 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 81.5 | -65.44% |
| 2021 | 236 | -36.8% |
| 2020 | 373 | 1812.12% |
| 2019 | 19.5 | 100.05% |
| 2018 | 9.75 | -52.51% |
| 2017 | 20.5 | 641.98% |
| 2016 | 2.77 | 30.1% |
| 2015 | 2.13 | -97.62% |
| 2014 | 89.3 | 72.14% |
| 2013 | 51.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Baxter BAX | 1.34 | -97.98% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | N/A | N/A | 🇺🇸 USA |
 CTI BioPharma
CTIC | 11.0 | -83.39% | 🇺🇸 USA |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Array Technologies ARRY | 1.98 | -97.01% | 🇺🇸 USA |